Safety and biocompatibility of injectable vaccine adjuvants composed of thermogelling block copolymer gels

Abstract

Injectable thermogelling polymers have been recently investigated as novel adjuvants and delivery systems for next generation vaccines. As research into natural and synthetic biocompatible polymers progresses, the safety and biocompatibility of these compounds is of paramount importance. We have developed cationic pentablock copolymer (PBC) vaccine adjuvants based on Pluronic F127, a thermogelling triblock copolymer that has been approved by the FDA for multiple applications, and methacrylated poly(diethyl amino)ethyl methacrylate outer blocks. These novel materials have been demonstrated to effectively create an antigen depot, minimally impact antigen stability, and enhance the immune response to antigens (i.e., adjuvanticity) in mice. In this work, we investigated the safety and biocompatibility of the parent triblock Pluronic gels and the cationic PBC gels in mice. Histological analysis showed no injection site reactions and no damage to the liver or kidneys was observed upon administering the block copolymer formulations. However, the subcutaneous injection of a thermogelling Pluronic solution induced increased levels of lipids in the blood, with no further deleterious effects observed from the addition of the cationic outer blocks. This hyperlipidemia resolved within 30 days after the administration of the Pluronic formulation. To mitigate this adverse effect, the vaccine adjuvant formulations were modified by adding poly(vinyl alcohol), which allowed gelation, while reducing the amount of Pluronic in the formulation. This modified formulation abrogated the observed hyperlipidemia and no adverse effects were observed in the serum through biomarker analysis or at the injection site (i.e., inflammation) in comparison to the responses induced by administration of saline or incomplete Freund's adjuvant. These studies provide a foundation to developing these gels as adjuvants for next generation vaccines. © 2019 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 107A: 1754–1762, 2019.

Document Details

Document Type
Pub Defense Publication
Publication Date
Apr 29, 2019
Source ID
10.1002/jbm.a.36691

Entities

People

  • Balaji Narasimhan
  • Justin R. Adams
  • Michael J. Wannemuehler
  • Shannon L. Haughney
  • Sujata Senapati
  • Surya Mallapragada

Organizations

  • Iowa State University
  • United States Army

Tags

Fields of Study

  • Biology

Readers

  • Immunology
  • Nanoscale Plasmonic Nanotechnology
  • Polymer Science and Engineering.

Technology Areas

  • Biotechnology
  • Biotechnology - Cancer Biotech
  • Microelectronics